Table 1 Baseline characteristics of patients at the time of CABG
Parameter | All patients Mean/Median (IQ)/% | No-scar Mean/Median (IQ)/% | Scar group Mean/Median (IQ)/% | p value |
|---|---|---|---|---|
Number of patients | 185 | 52 | 133 | |
Age (years) | 63.2 (11.5) | 64.2 (9.7) | 62.8 (12.2) | 0.47 |
Male (%) | 71.9 | 55.8 | 78.2 | 0.002 |
Body Mass Index(BMI) | 28.3 (5.1) | 28.0 (5.8) | 28.4 (4.8) | 0.60 |
History Of Smoking (%) | 63.2 | 57.7 | 65.4 | 0.33 |
Diabetes Mellitus (%) | 34.6 | 25.0 | 38.3 | 0.09 |
Hypertension (%) | 78.4 | 76.9 | 78.9 | 0.76 |
History of Prior MI (%) | 63.8 | 38.5 | 73.7 | <0.0001 |
Cerebrovascular Disease (%) | 14 | 15.4 | 13.5 | 0.75 |
Peripheral artery disease (%) | 20 | 23.1 | 18.8 | 0.5130 |
Dyslipidemia (%) | 70.8 | 65.4 | 72.9 | 0.31 |
Previous CABG history (%) | 5.4 | 0.0 | 7.5 | 0.06 |
Glomerular filtration rate | 68.32 (25.20) | 66.0 (25.7) | 69.2 (25.0) | 0.44 |
Chronic Lung Disease (%) | 17.8 | 21.1 | 16.5 | 0.46 |
B - Blocker (%) | 78.9 | 73.1 | 81.2 | 0.2232 |
ACE - Inhibitor (%) | 56.8 | 51.9 | 58.7 | 0.4067 |
Aspirin (%) | 91.4 | 86.5 | 93.2 | 0.1548 |
Lipid lowering therapy (%) | 71.6 | 64.3 | 74.8 | 0.2076 |
LVEDV (ml) | 210.75 (77.79) | 195.44 (86.20) | 216.82 (73.65) | 0.0936 |
LVESV (ml) | 134.29 (77.40) | 118.88 (86.76) | 140.40 (72.80) | 0.0899 |
ESVi (ml/m2) | 29.77 (18.53, 46.19) | 24.67 (12.62, 41.66) | 32.39 (19.84, 46.98) | 0.0424 |
LVEF (%) | 38 (28,52) | 45 (25,65) | 37 (28,49) | 0.038 |
Number of Segments scar | 2 (0,5) | 0 | 3 (2,6) | NA |
STS % mortality risk | 1.4 (0.8,2.8) | 1.4 (0.7,2.6) | 1.4 (0.7,2.9) | 0.71 |
Cardiopulmonary Bypass (%) | 63.8 | 61.5 | 64.7 | 0.6911 |
Number of vessels bypassed | 4 (3–4) | 3.5 (2–4) | 4 (3–4) | 0.5929 |